The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 22, 2019

Filed:

Oct. 20, 2017
Applicant:

Sunovion Pharmaceuticals Inc., Marlborough, MA (US);

Inventors:

Scott David Barnhart, York, PA (US);

Michael Clinton Koons, York, PA (US);

Madhu Sudan Hariharan, Greensboro, NC (US);

Jordan Dubow, Glencoe, IL (US);

Thierry Bilbault, Toronto, CA;

Anthony John Giovinazzo, Caledon, CA;

Assignee:

Sunovion Pharmaceuticals Inc., Marlborough, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 47/02 (2006.01); A61K 31/473 (2006.01); A61K 45/06 (2006.01); A61K 47/14 (2017.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01); A61K 9/70 (2006.01); A61P 25/16 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/38 (2006.01);
U.S. Cl.
CPC ...
A61K 9/006 (2013.01); A61K 9/7007 (2013.01); A61K 31/473 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01); A61K 47/38 (2013.01); A61P 25/16 (2018.01);
Abstract

Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an 'off' episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.


Find Patent Forward Citations

Loading…